Min­neso­ta judge nar­rows charges in class ac­tion suit against My­lan, phar­ma­cy ben­e­fit man­agers over EpiPen price hikes

Sec­ond time’s the charm for Vi­a­tris and a suite of phar­ma­cy ben­e­fit man­agers in a pro­posed class-ac­tion law­suit al­leg­ing col­lu­sion over price hikes for the com­pa­ny’s EpiPen.

Af­ter try­ing — and suc­ceed­ing, in part — to get claims against them dis­missed back in 2021, the de­fen­dants cel­e­brat­ed a win on Tues­day when a Min­neso­ta fed­er­al judge dis­missed a large chunk of the claims due to a lack of ev­i­dence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER